论文部分内容阅读
目的:肿瘤RNA致敏树突状细胞(DC)治疗颅内荷瘤小鼠,观察DC疫苗对脑胶质瘤的治疗作用,探讨免疫反应的机理,为DC疫苗的临床应用提供实验基础。方法:用G422胶质母细胞瘤RNA冲击致敏DC制成DC疫苗,检测DC疫苗的CTL活性,瘤内和皮下两种途径注射荷瘤小鼠以进行免疫治疗,观察小鼠生存期,并与PBS、单纯DC组进行比较,同时检测血清IFN-γ、IL-2、IL-10、IL-4等细胞因子,并行病理检查。结果:DC疫苗的CTL活性明显高于对照组(P<0.01)。两种途径注射DC疫苗,治疗组小鼠生存时间均明显延长(P<0.01),血清IFN-γ显著升高(P<0.01),IL-10明显下降(P<0.05),病理提示肿瘤出现坏死。两种注射途径间以上指标无明显差异。结论:肿瘤RNA冲击致敏DC注射荷瘤小鼠具有明显的免疫治疗作用,能显著延长动物生存期,并能诱导特异性抗肿瘤细胞免疫反应,其机理主要是Th1细胞介导的细胞免疫反应,且免疫反应的程度与注射途径无关。
Objective: To investigate the therapeutic effect of DC vaccine on glioma in mice with intracranial tumor-bearing tumor by RNA-sensitized dendritic cells (DCs), and to explore the mechanism of immune response to provide the experimental basis for the clinical application of DC vaccine. Methods: The DC vaccine was sensitized by G422 glioblastoma RNA and the CTL activity of DC vaccine was tested. The tumor-bearing mice were injected intratumorally and subcutaneously for immunotherapy. The survival of mice was observed. Compared with PBS group and pure DC group, cytokines such as IFN-γ, IL-2, IL-10 and IL-4 were detected simultaneously and pathologically. Results: The CTL activity of DC vaccine was significantly higher than that of control group (P <0.01). Both of the two routes of injection of DC vaccine significantly prolonged the survival time (P <0.01), the level of IFN-γ in serum increased (P <0.01) and IL-10 decreased significantly Necrosis. There is no significant difference between the above two ways of injection. CONCLUSION: Tumor RNA-sensitized DCs injected with tumor-bearing mice have obvious immunotherapy effect, which can significantly prolong the survival of animals and induce specific anti-tumor immune responses. The mechanism is mainly Th1-mediated cellular immune response , And the degree of immune response has nothing to do with the injection route.